Oncology At A Glance (eBook)

Graham G. Dark, Lindsay Hennah (Autoren)

eBook Download: EPUB

2025 | 2. Auflage
543 Seiten
Wiley (Verlag)
978-1-394-29270-7 (ISBN)

Infos

The market-leading at a Glance series is popular among healthcare students and newly qualified practitioners for its concise and simple approach and excellent illustrations.

Each bite-sized chapter is covered in a double-page spread with clear, easy-to-follow diagrams supported by succinct explanatory text.

Covering a wide range of topics, books in the at a Glance series are ideal as introductory texts for teaching, learning and revision, and are useful throughout university and beyond.

Everything you need to know about Oncology... at a Glance!

Discover a comprehensive, newly-revised edition of Oncology at a Glance!

Oncology at a Glance demystifies the complexities of cancer biology and treatment for medical students and junior healthcare practitioners. With updated content including emerging therapies, multidisciplinary team approaches, and palliative care, Oncology at a Glance, Second Edition bridges gaps in the often-fragmented exposure to oncology during clinical training. Real-world case studies and accompanying exercises deepen comprehension, enhance understanding, and support problem-solving in oncology practice.

Ideal for foundational learning or a quick refresher in clinical practice, Oncology at a Glance, Second Edition:

• Consolidates key information into concise sections on individual cancers and broader oncological principles
• Covers foundational cancer biology, investigation, clinical management, and key human issues such as communication and palliative care
• Includes multiple-choice questions, self-assessment exercises, and a companion website with interactive self-testing features

Developed with feedback from medical students to ensure relevance and clarity, Oncology at a Glance, Second Edition remains a must-have for undergraduate medical students, nursing students, junior doctors, and allied health professionals.

All content reviewed by students for students

Wiley Health Science books are designed exactly for their intended audience. All of our books are developed in collaboration with students. This means that our books are always published with you, the student, in mind.

If you would like to be one of our student reviewers, go to www.reviewnursingbooks.com to find out more.

This title is also available as an e-book. For more details, please see www.wiley.com/buy/9781394292691

DR. GRAHAM G. DARK is a Senior Lecturer in Cancer Education and Honorary Consultant in Medical Oncology at Newcastle University. He authored the speciality curriculum for Medical Oncology and chairs the Specialty Certificate Examination Board at the Royal College of Physicians, London. He is a Fellow of multiple international cancer education associations.

DR. LINDSAY HENNAH is a Specialty Registrar in Medical Oncology at Freeman Hospital, Newcastle upon Tyne. With a focus on gynaecological cancers and medical education, she actively contributes to advancing oncology training. She is a member of the Exam Board for the Specialty Certificate Examination in Medical Oncology.

Textauszug

Abbreviations

5‐HIAA

5‐hydroxyindoleacetic acid

5‐HT

5‐hydroxytryptamine (serotonin)

5‐HTP

5‐hydroxytryptophan

ACCS

acute common core stem

ACE

angiotensin converting enzyme

ACTH

adrenocorticotrophic hormone

ADH

antidiuretic hormone or vasopressin

ADT

androgen deprivation therapy

AFP

alpha feto‐protein

ALK

anaplastic lymphoma kinase

ALL

acute lymphoblastic leukaemia

AML

acute myeloid leukaemia

AOS

acute oncology service

ARCP

annual review of competency progression

ATG

antithymocyte globulin

aTNM

autopsy classification of stage

ATP

adenosine triphosphate

BCC

basal cell carcinoma

BCG

Bacillus Calmette–Guérin

BEP

bleomycin, etoposide, cisplatin chemotherapy

BMT

bone marrow transplant

BP

blood pressure

BSO

bilateral salpingo‐oophorectomy

CACS

cancer anorexia and cachexia syndrome

CAR T

chimeric antigen receptor T‐cell therapy

CCT

certificate of completed training

CD

cluster of differentiation

CDK

cyclin‐dependent kinase

CEA

carcinoembryonic antigen

CHART

continuous hyperfractionated radiotherapy

CHRPE

congenital hypertrophy of the retinal pigment epithelium

CIN

cervical intraepithelial neoplasia

CINV

chemotherapy‐induced nausea and vomiting

CIS

carcinoma in‐situ

CLL

chronic lymphocytic leukaemia

CML

chronic myeloid leukaemia

CMT

core medical training

CNS

central nervous system

COCP

combined oral contraceptive pill

COX

cyclooxygenase

CR

complete response

CRP

C‐reactive protein

CSF

cerebrospinal fluid

CT

computed tomography

CTC

common toxicity criteria

ctDNA

circulating tumour DNA

CTLA4

cytotoxic T‐lymphocyte antigen 4

cTNM

clinical classification of stage

CTZ

chemoreceptor trigger zone

CUP

carcinoma of unknown primary

CVA

cerebrovascular accident

CXR

chest X‐ray

DCIS

ductal carcinoma in situ

DLT

dose‐limiting toxicity

dMMR

deficient mismatch repair

DNA

deoxyribonucleic acid

DRR

digitally reconstructed radiograph

DVT

deep vein thrombosis

EBV

Epstein‐Barr virus

ECM

extracellular matrix

ECOG

Eastern Cooperative Oncology Group

EGFR

epidermal growth factor receptor

EM

electron microscopy

EMA

epithelial membrane antigen

EMT

epithelial‐mesenchymal transformation

ENT

ear nose and throat

ER

oestrogen receptor/emergency room

ERCP

endoscopic retrograde cholangiopancreatography

ESMO

European Society for Medical Oncology

ESR

erythrocyte sedimentation rate

eV

electron volt

FAP

familial adenomatous polyposis

FBC

full blood count

FDG

fluorodeoxyglucose

FGF

fibroblast growth factor

FIGO

International Federation of Gynaecology and Obstetrics

FISH

fluorescent in‐situ hybridisation

FIT

faecal immunochemical test

FNA

fine needle aspiration

FOB

faecal occult blood

FSH

follicle stimulating hormone

G‐CSF

granulocyte‐colony stimulating factor

GCT

germ cell tumour

GFR

glomerular filtration rate

GI

gastrointestinal

GIST

gastrointestinal stromal tumour

GU

genitourinary

Gy

Gray

HAD

hospital anxiety and depression scale

HBV

hepatitis B virus

HCC

hepatocellular carcinoma

hCG

human chorionic gonadotrophin

HCV

hepatitis C virus

HGF

hepatocyte growth factor

HHV

human herpes virus

HIV

human immunodeficiency virus

HNPCC

hereditary non‐polyposis colorectal cancer

HOA

hypertrophic osteoarthropathy

HPV

human papilloma virus

HRT

hormone replacement therapy

HTLV‐1

human T‐cell lymphotrophic virus‐1

ICP

intracranial pressure

ICPi

immune checkpoint inhibitor

IDA

iron deficiency anaemia

IGF

insulin‐like growth factor

IHC

immunohistochemistry

IL

interleukin

IMRT

intensity modulated radiotherapy

IQ

intelligence quotient

IV

intravenous

IVC

inferior vena cava

JVP

jugular venous pressure

LCIS

lobular carcinoma in situ

LD

longest diameter

LDH

lactate dehydrogenase

LEMS

Lambert–Eaton myasthenic syndrome

LFT

liver function tests

LH

leutenising hormone

LHRH

luteinising hormone releasing hormone

mAb

monoclonal antibody

MALT

mucosa‐associated lymphoid tissue

MAP

mitogen‐activated protein

MDT

multidisciplinary team

MEN

multiple endocrine neoplasia

mIBG

meta‐iodobenzylguanidine

MMF

mycophenolate

MMR

mismatch repair

MR/MRI

magnetic resonance imaging

MRCP

magnetic resonance cholangiopancreatography

MSCC

malignant spinal cord compression

MSU

mid stream urine

MTD

maximum tolerated dose

mTOR

mammalian target of rapamycin

NAFLD

non‐alcoholic fatty liver disease

NER

nucleotide excision repair

NET

neuroendocrine tumour

NHL

non‐Hodgkin lymphoma

NHS

National Health Service

NK‐1

neurokinin‐1

NOS

not otherwise specified

NSAID

non‐steroidal anti‐inflammatory drug

NSCLC

non‐small cell lung cancer

NSE

neurone‐specific enolase

NSGCT

non‐seminomatous germ cell tumour

NTRK

neurotrophic tyrosine receptor kinase

OS

overall survival

PARP

poly (ADP‐ribose) polymerase

PCOS

polycystic ovarian syndrome

PD

progressive disease

PD‐1

programmed cell death 1

PDGF

platelet‐derived growth factor

PD‐L1

programmed cell death ligand 1

PE

pulmonary...

Produkt-Details

• Erscheint lt. Verlag: 16.4.2025
• Reihe/Serie: At a Glance
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete
• Schlagworte: cancer management guide • clinical oncology quick reference • oncology case studies • oncology education • oncology reference guide • oncology revision guide • oncology study guide • oncology textbook • oncology training • palliative care guide
• ISBN-10: 1-394-29270-8 / 1394292708
• ISBN-13: 978-1-394-29270-7 / 9781394292707